nach oben

Clinical and Translational Oncology

Erschienen in:

01.12.2012 | Research Article

Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model

verfasst von: Guillaume Passot, Aurélien Dupré, Michel Rivoire, Faheez Mohamed, Naoual Bakrin, Olivier Glehen

Erschienen in: Clinical and Translational Oncology | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is currently the only potentially curative treatment for peritoneal carcinomatosis (PC). Systemic administration of bevacizumab improves survival in patients with metastatic colorectal or ovarian cancer. Intraperitoneal administration of bevacizumab has been shown to be safe and effective in treating malignant ascites. The combination of CRS with intraperitoneal (IP) bevacizumab could maximize local control and survival from PC, but the associated morbidity from this is unknown. The aim of this study was to evaluate the safety of the combination of CRS with IP bevacizumab and to determine the pharmacokinetics of the drug in a rabbit model.

Methods

Twenty healthy rabbits underwent a standardized procedure of debulking surgery, including peritonectomy and gastrointestinal anastomosis and were randomized to receive IP bevacizumab (25 mg/kg) or placebo. Another group of three rabbits underwent an instillation of IP bevacizumab (25 mg/kg) without surgery.

Results

One rabbit that received IP bevacizumab died with no complication associated with the use of bevacizumab at autopsy. There was no significant difference between IP bevacizumab and placebo in weight loss, length of surgery or morbidity. The plasma concentration of bevacizumab increased to a peak at 24 h post IP administration. Bevacizumab was not detected in the plasma of animals without surgery.

Conclusion

This study suggests that IP bevacizumab does not increase morbidity and mortality of debulking surgery in an animal model. When surgery is performed, the pharmacokinetics of IP bevacizumab are modified in plasma.

Garcia-Carbonero R, Paz-Ares L (2006) Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 32(6):676–681PubMedCrossRef

Cotte E, Passot G, Mohamed F, Vaudoyer D, Gilly FN, Glehen O (2009) Management of peritoneal carcinomatosis from colorectal cancer: current state of practice. Cancer J 15(3):243–248PubMedCrossRef

Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M et al (2004) Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 22(16):3284–3292PubMedCrossRef

Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834PubMedCrossRef

Sugarbaker PH (2006) New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol 7(1):69–76PubMedCrossRef

Cotte E, Glehen O, Mohamed F, Lamy F, Falandry C, Golfier F, Gilly FN (2007) Cytoreductive surgery and intraperitoneal chemo-hyperthermia for chemo-resistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31(9):1813–1820PubMedCrossRef

Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342PubMedCrossRef

Cao Y, Tan A, Gao F, Liu L, Liao C, Mo Z (2009) A meta-analysis of randomized controlled trials comparing chemotherapy plus bevacizumab with chemotherapy alone in metastatic colorectal cancer. Int J Colorectal Dis 24(6):677–685PubMedCrossRef

Burger RA (2007) Experience with bevacizumab in the management of epithelial ovarian cancer. J Clin Oncol 25(20):2902–2908PubMedCrossRef

10.

Cannistra SA, Matulonis UA, Penson RT, Hambleton J, Dupont J, Mackey H et al (2007) Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 25(33):5180–5186PubMedCrossRef

11.

Burger RA, Sill MW, Monk BJ, Greer BE, Sorosky JI (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25(33):5165–5171PubMedCrossRef

12.

Mesiano S, Ferrara N, Jaffe RB (1998) Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol 153(4):1249–1256PubMedCrossRef

13.

Logan-Collins JM, Lowy AM, Robinson-Smith TM, Kumar S, Sussman JJ, James LE et al (2008) VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 15(3):738–744PubMedCrossRef

14.

Yoshikawa T, Tsuburaya A, Miyagi Y, Sekiguchi H, Kimura M, Cho H et al (2006) Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer. Anticancer Res 26(5B):3849–3853PubMed

15.

Kobold S, Hegewisch-Becker S, Oechsle K, Jordan K, Bokemeyer C, Atanackovic D (2009) Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 14(12):1242–1251PubMedCrossRef

16.

Hamilton CA, Maxwell GL, Chernofsky MR, Bernstein SA, Farley JH, Rose GS (2008) Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol 111(3):530–532PubMedCrossRef

17.

Glockzin G, Schlitt HJ, Piso P (2009) Peritoneal carcinomatosis: patients selection, perioperative complications and quality of life related to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. World J Surg Oncol 7:5PubMedCrossRef

18.

McCormack PL, Bevacizumab KS (2008) A review of its use in metastatic colorectal cancer. Drugs 68(4):487–506PubMedCrossRef

19.

August DA, Serrano D, Poplin E (2008) “Spontaneous,” delayed colon and rectal anastomotic complications associated with bevacizumab therapy. J Surg Oncol 97(2):180–185PubMedCrossRef

20.

Scappaticci FA, Fehrenbacher L, Cartwright T, Hainsworth JD, Heim W, Berlin J et al (2005) Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 91(3):173–180PubMedCrossRef

21.

Ranpura V, Pulipati B, Chu D, Zhu X, Wu S (2010) Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis. Am J Hypertens 23(5):460–468PubMedCrossRef

22.

Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A et al (2006) Preoperative plasma vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol 103(2):512–517PubMedCrossRef

23.

DinizBizzo SMMD, Lima JM, Mororó Jda S, Casali-da-Rocha JC, Ornellas MH (2010) Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer. Int J Gynaecol Obstet 2010109(2):113–117CrossRef

24.

Jain RK (2001) Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 7(9):987–989PubMedCrossRef

25.

Zondor SD, Medina PJ (2004) Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 38(7–8):1258–1264PubMed

26.

Gerber HP, Ferrara N (2005) Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res 65(3):671–680PubMed

27.

Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT et al (2004) Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 10(2):145–147PubMedCrossRef

28.

Sun WL, Hutarew G, Gradl J, Gratzl M, Denz H, Fiegl M (2009) Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine. Cancer Biol Ther 8(15):1459–1462PubMedCrossRef

29.

Yagi Y, Fushida S, Harada S, Tsukada T, Kinoshita J, Oyama K et al (2011) Biodistribution of humanized anti-VEGF monoclonal antibody/bevacizumab on peritoneal metastatic models with subcutaneous xenograft of gastric cancer in mice. Cancer Chemother Pharmacol 66(4):745–753CrossRef

30.

Imaizumi T, Aoyagi K, Miyagi M, Shirouzu K (2010) Suppressive effect of bevacizumab on peritoneal dissemination from gastric cancer in a peritoneal metastasis model. Surg Today 40(9):851–857PubMedCrossRef

31.

Ninomiya S, Inomata M, Tajima M, Ali AT, Ueda Y, Shiraishi N et al (2009) Effect of bevacizumab, a humanized monoclonal antibody to vascular endothelial growth factor, on peritoneal metastasis of MNK-45P human gastric cancer in mice. J Surg Res 154(2):196–202PubMedCrossRef

32.

Dedrick RLMC, Bungay PM, DeVita VT Jr (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11PubMed

33.

Dedrick RL, Flessner MF (1997) Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. J Natl Cancer Inst 89(7):480–487PubMedCrossRef

34.

Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG (1989) Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 49(12):3380–3384PubMed

35.

Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE, Young RC (1979) Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 39(8):3209–3214PubMed

36.

Shah DKSB, Veith J, Tóth K, Bernacki RJ, Balthasar JP (2009) Use of an anti-vascular endothelial growth factor antibody in a pharmacokinetic strategy to increase the efficacy of intraperitoneal chemotherapy. J Pharmacol Exp Ther 329(2):580–591PubMedCrossRef

37.

Choi YI, Lee SH, Ahn BK, Baek SU, Park SJ, Kim YS et al (2008) Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin). Cancer Res Treat 40(1):33–35PubMedCrossRef

38.

Hapani S, Chu D, Wu S (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 10(6):559–568PubMedCrossRef

39.

Lin YS, Nguyen C, Mendoza JL, Escandon E, Fei D, Meng YG, Modi NB (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288:371–378PubMed

40.

Loisel S, Ohresser M, Pallardy M, Dayde D, Berthou C, Cartron G et al (2007) Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol 62(1):34–42PubMedCrossRef

41.

Belizon A, Balik E, Feingold DL, Bessler M, Arnell TD, Forde KA et al (2006) Major abdominal surgery increases plasma levels of vascular endothelial growth factor: open more so than minimally invasive methods. Ann Surg 244(5):792–798PubMedCrossRef

Titel: Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model
verfasst von: Guillaume Passot
Aurélien Dupré
Michel Rivoire
Faheez Mohamed
Naoual Bakrin
Olivier Glehen
Publikationsdatum: 01.12.2012
Verlag: Springer Milan
Erschienen in: Clinical and Translational Oncology / Ausgabe 12/2012
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-012-0888-x

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Intraperitoneal bevacizumab combined with cytoreductive surgery: a pre-clinical study of tolerance and pharmacokinetics in an animal model

Abstract

Introduction

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2012

Comments on “SEOM guidelines for endometrial cancer”

Helicobacter pylori infection of the larynx may be an emerging risk factor for laryngeal squamous cell carcinoma

Role of gamma-delta T-cells in cancer. Another opening door to immunotherapy

Functional and biologic metrics for predicting radiation pneumonitis in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy

Depicting the evolving scenario of translational-guided drug development

Characteristics and long-term survival of colorectal cancer patients aged 44 years and younger

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie